SCAI: 3 late-breaking clinical trials on docket

The Society for Cardiovascular Angiography and Interventions (SCAI) annual scientific sessions, scheduled for May 8 through 11 in Orlando, will offer late-breaking clinical trials, a congenital heart disease symposium, coronary, peripheral and structural tracks and more.

Late-breakers include:

  • VERITAS (Transcatheter Aortic Valve Intervention-Live Transmission Study), an international clinical trial designed to evaluate safety of patients who underwent transcatheter aortic valve intervention (TAVI) during a live case or video-taped transmission compared with patients who underwent TAVI without procedure transmission. Ron Waksman, MD, of Washington Hospital Center in Washington, D.C., will present results.
  • POSEIDON (Prevention of Contrast Renal Injury with Different Hydration Strategies), a randomized controlled trial that assesses two hydration protocols for the prevention of contrast medium-induced nephropathy. One group in the trial received standard therapy with hydration with 0.9 percent saline, and a second group received left ventricular end diastolic pressure-guided hydration with 0.9 percent saline. Somjot Brar, MD, MPH, of Kaiser Permanente in Los Angeles, will present findings.
  • Angioplasty following Carotid Stent Deployment Reduces the Risk of Restenosis and May or May Not Increase the Risk of Procedure Related Stroke, offered by Mahmoud Malas, MD, director of endovascular surgery at Johns Hopkins Hospital and Bayview Medical Center in Baltimore.